Cytek Biosciences, Inc. CTKB Change in Deferred Revenue
Change in Deferred Revenue at other companies
Other financials
Where this comes from
Reported directly by Cytek Biosciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInDeferredRevenue.
The official record: Cytek Biosciences, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Cytek Biosciences, Inc.'s change in deferred revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Cytek Biosciences, Inc.'s change in deferred revenue?
- Cytek Biosciences, Inc. (CTKB) reported change in deferred revenue of $1.18M in Q1 2026.
- How has Cytek Biosciences, Inc.'s change in deferred revenue changed year-over-year?
- Cytek Biosciences, Inc.'s change in deferred revenue decreased by 12.5% year-over-year, from $1.34M to $1.18M.
- What is the long-term trend for Cytek Biosciences, Inc.'s change in deferred revenue?
- Over 3 years (2021 to 2025), Cytek Biosciences, Inc.'s change in deferred revenue has grown at a -28.9% compound annual growth rate (CAGR), from $10.01M to $3.6M.
- What does change in deferred revenue mean?
- Change in payments received from customers for goods/services not yet delivered — a key SaaS and subscription metric.